/

MBRX

Moleculin Biotech, Inc.Closed

0.4352+0.02 +5.38%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 0.4375 +0.53%

Open

0.4240

Prev close

0.4130

Day range

0.41020.4361

52-week range

0.161015.75

Volume

180.86K0.14×

Mkt cap

8.87M

P/E ttm

0.05

Fwd P/E

-0.00

EPS ttm

8.98

Div yield

0.00%

Earnings

—

From 52w high

−97.24%

Price Chart

Yahoo Finance · delayed

MBRXOct 13, 2026O 0.4240H 0.4360L 0.4100C 0.4350+0.0210 (+5.07%)Vol 181.60K

SMA 500.5801
SMA 2002.2469

1Y change −96.28% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

MBRX Moleculin Biotech, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −2.47%
1 month: −39.16%
3 months: −80.75%
6 months: −82.53%
Year to date: −86.86%
1 year: −96.28%

Valuation & ownership

Market cap: 8.87M
Enterprise value: 1.51M
P/E (ttm): 0.05
Forward P/E: -0.00
PEG ratio: —
Price / book: 0.27
Price / sales (ttm): —
EV / EBITDA: -0.05
EPS (ttm): 8.98
EPS (forward): -110.50
Beta (5y monthly): 2.00
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 20.39M
Float: 17.03M
Short % of float: 1.01%
Short ratio (days): 0.17
Held by insiders: 6.13%
Held by institutions: 8.19%
Avg volume (3m): 1.31M
50-day average: 0.5799
200-day average: 2.26
52-week change: −96.28%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 34.9
vs 50-day SMA: −25.02%
vs 200-day SMA: −80.64%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 15.54%
Realised vol (20d, ann.): 160.2%
From 52-week high: −97.24%
From 52-week low: +170.19%

ANR

Analyst Consensus

3 analysts

Consensus

Strong buy

1.33 on a 1 (strong buy) – 5 (sell) scale

Mean target

12.00

+2,657.35% implied

Low 2.00Median 3.00High 31.00

Recommendation trend

Now3 / 0 / 0
1m ago3 / 0 / 0

DES

About Moleculin Biotech, Inc.

Yahoo Finance profile

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Sector: Healthcare
Industry: Biotechnology
Employees: 17
Headquarters: Houston, TX, United States
Website: moleculin.com
Officers: Mr. Walter V. Klemp Chairman, President & CEO
Mr. Jonathan P. Foster CPA Executive VP & CFO
Dr. Donald H. Picker Ph.D. Chief Scientific Officer
Dr. Waldemar Priebe Ph.D.

SEAS

Seasonality · MBRX

2016–2026 · monthly returns

Strongest month Jul +17.45%Weakest month Oct −14.11%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	29.6	-44.3	-4.2	11.8	9.0	0.0	-85.7	61.2	-22.5	-13.0			−86.9%
2025	-11.2	-14.6	-24.5	8.8	-17.9	-65.3	107.9	-37.6	35.2	-12.3	-41.3	-51.5	−92.2%
2024	-41.3	24.8	-37.4	-15.1	-5.0	-26.2	-10.5	-19.0	11.4	-8.5	6.5	-38.6	−86.8%
2023	18.9	-4.0	-20.7	-22.2	-15.1	-8.7	9.3	-11.5	-23.6	11.0	26.1	43.2	−19.1%
2022	-18.8	-7.9	28.1	-10.7	-5.7	-3.3	16.6	-12.4	-28.4	-5.7	44.0	-26.4	−43.0%
2021	4.0	-15.0	-3.5	-14.0	5.4	-0.8	-15.0	-1.3	-2.6	-12.0	-21.6	-10.1	−61.1%
2020	-4.9	-22.9	-9.1	78.7	0.0	-11.2	18.8	-23.7	-7.3	-15.0	12.9	2.2	−12.9%
2019	28.8	-0.7	-39.1	66.7	-11.1	4.2	-12.8	3.7	-1.8	-3.6	-5.6	-9.4	−12.0%
2018	1.1	5.9	-9.5	1.1	-1.1	-0.6	-5.0	1.2	-7.0	-35.0	26.0	-20.6	−44.1%
2017	-21.9	-36.0	2.6	-22.2	-16.5	146.1	59.9	-15.7	-5.2	-19.2	-17.6	17.0	−18.4%
2016							5.3	-11.2	-7.9	-40.8	-19.8	-15.9	−65.6%

INSD

Insider Activity · MBRX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Aug 2, 2026	Picker Donald HOfficer	Purchase at price 0.42 per share.	173.3K	$73.67K
Aug 2, 2026	Klemp Walter V.Chief Executive Officer	Purchase at price 0.42 per share.	533.3K	$226.67K
Aug 2, 2026	Foster Jonathan P.Chief Financial Officer	Purchase at price 0.42 per share.	293.3K	$124.67K
Jun 21, 2026	Picker Donald HOfficer	—	115	—
Jun 21, 2026	Klemp Walter V.Chief Executive Officer	—	510	—
Jun 21, 2026	Foster Jonathan P.Chief Financial Officer	—	283	—
Nov 3, 2025	Picker Donald HOfficer	—	8.8K	—
Nov 3, 2025	Klemp Walter V.Chief Executive Officer	—	28.8K	—
Nov 3, 2025	Foster Jonathan P.Chief Financial Officer	—	20.6K	—
Jun 22, 2025	Klemp Walter V.Chief Executive Officer	Purchase at price 0.37 per share.	675.7K	$250.00K
Jun 22, 2025	Foster Jonathan P.Chief Financial Officer	Purchase at price 0.37 per share.	270.3K	$100.00K
Jun 19, 2025	Picker Donald HOfficer	—	2.8K	—
Jun 19, 2025	Klemp Walter V.Chief Executive Officer	—	12.7K	—
Jun 19, 2025	Foster Jonathan P.Chief Financial Officer	—	7K	—
Jun 15, 2025	Klemp Walter V.Chief Executive Officer	—	1.7K	—
Jun 15, 2025	Foster Jonathan P.Chief Financial Officer	—	833	—

MBRX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

MBRX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Moleculin Biotech, Inc.

Seasonality · MBRX

Insider Activity · MBRX

Congress Trades · MBRX

Investors Holding MBRX

Investors Holding MBRX

Congress Trades · MBRX

Insider Activity · MBRX

Seasonality · MBRX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Moleculin Biotech, Inc.

Financial Snapshot

Earnings & Dividends

News